Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.

Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D.

J Leukoc Biol. 2005 Aug;78(2):359-71. Epub 2005 Jun 3.

PMID:
15937142
2.

Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Gomez GG, Read SB, Gerschenson LE, Santoli D, Zweifach A, Kruse CA.

Neuro Oncol. 2004 Apr;6(2):83-95.

3.

New insights on disintegrin-receptor interactions: eristostatin and melanoma cells.

McLane MA, Kuchar MA, Brando C, Santoli D, Paquette-Straub CA, Miele ME.

Haemostasis. 2001 May-Dec;31(3-6):177-82.

4.
5.

Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.

Geoerger B, Tang CB, Cesano A, Visonneau S, Marwaha S, Judy KD, Sutton LN, Santoli D, Phillips PC.

Neuro Oncol. 2000 Apr;2(2):103-13. doi: 10.1093/neuonc/2.2.103.

6.

N-(n-Benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: a potential ligand for PET imaging of breast cancer.

Shiue C, Shiue GG, Benard F, Visonneau S, Santoli D, Alavi AA.

Nucl Med Biol. 2000 Nov;27(8):763-7.

PMID:
11150709
7.

The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.

Kruse CA, Visonneau S, Kleinschmidt-DeMasters BK, Gup CJ, Gomez GG, Paul DB, Santoli D.

Cancer Res. 2000 Oct 15;60(20):5731-9.

8.

Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.

Visonneau S, Cesano A, Porter DL, Luger SL, Schuchter L, Kamoun M, Torosian MH, Duffy K, Sickles C, Stadtmauer EA, Santoli D.

Clin Cancer Res. 2000 May;6(5):1744-54.

9.

Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104.

Visonneau S, Cesano A, Jeglum KA, Santoli D.

Oncol Rep. 1999 Nov-Dec;6(6):1181-8.

PMID:
10523677
10.

Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104.

Visonneau S, Cesano A, Jeglum KA, Santoli D.

Clin Cancer Res. 1999 Jul;5(7):1868-75.

11.

Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice.

Cesano A, Visonneau S, Tran T, Santoli D.

Int J Oncol. 1999 Feb;14(2):245-51.

PMID:
9917498
12.

Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.

Cesano A, Wortman JA, Pourdehnad M, Visonneau S, Mozley D, Bhatnagar A, Alavi A, Santoli D.

Int J Oncol. 1999 Feb;14(2):233-44.

PMID:
9917497
13.

Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.

Visonneau S, Cesano A, Torosian MH, Santoli D.

Clin Cancer Res. 1997 Sep;3(9):1491-500.

14.
15.

TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.

Cesano A, Visonneau S, Santoli D.

Anticancer Res. 1998 Jul-Aug;18(4A):2289-95.

PMID:
9703868
16.

Opposite effects of linoleic acid and conjugated linoleic acid on human prostatic cancer in SCID mice.

Cesano A, Visonneau S, Scimeca JA, Kritchevsky D, Santoli D.

Anticancer Res. 1998 May-Jun;18(3A):1429-34.

PMID:
9673351
17.

Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice.

Visonneau S, Cesano A, Torosian MH, Miller EJ, Santoli D.

Am J Pathol. 1998 May;152(5):1299-311.

18.

Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells.

Cesano A, Visonneau S, Deaglio S, Malavasi F, Santoli D.

J Immunol. 1998 Feb 1;160(3):1106-15.

19.

Potent tumoricidal effects of a human cytotoxic T-cell line (TALL-104) against prostate cancer.

Umiel T, Campbell M, Cho S, Deem R, Cesano A, Santoli D, Koeffler H.

Int J Oncol. 1997 Jun;10(6):1125-31.

PMID:
21533494
20.

Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.

Cesano A, Visonneau S, Rovera G, Santoli D.

Anticancer Res. 1997 May-Jun;17(3C):1887-92.

PMID:
9216640
21.

Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.

Cesano A, Visonneau S, Wolfe JH, Jeglum KA, Fernandez J, Gillio A, O'Reilly RJ, Santoli D.

Cancer Immunol Immunother. 1997 May;44(3):125-36.

PMID:
9191872
22.

Conjugated linoleic acid suppresses the growth of human breast adenocarcinoma cells in SCID mice.

Visonneau S, Cesano A, Tepper SA, Scimeca JA, Santoli D, Kritchevsky D.

Anticancer Res. 1997 Mar-Apr;17(2A):969-73.

PMID:
9137436
23.
24.

Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.

Cesano A, Visonneau S, Jeglum KA, Owen J, Wilkinson K, Carner K, Reese L, Santoli D.

Cancer Res. 1996 Jul 1;56(13):3021-9.

26.

Clonal expansion of germline B-lineage acute lymphoblastic leukemia in severe combined immunodeficient mice.

Felix CA, Wasserman R, Cesano A, Nowell PC, Hosler MR, Masterson M, Poplack DG, Santoli D.

Oncogene. 1995 Nov 2;11(9):1753-9.

PMID:
7478603
28.

Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.

Cesano A, Visonneau S, Cioé L, Clark SC, Santoli D.

Cancer Immunol Immunother. 1995 Mar;40(3):139-51.

PMID:
7728772
29.
30.

Effects of fatty acids on proliferation and activation of human synovial compartment lymphocytes.

DeMarco DM, Santoli D, Zurier RB.

J Leukoc Biol. 1994 Nov;56(5):612-5.

PMID:
7964169
31.

Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.

Cesano A, Visonneau S, Cioé L, Clark SC, Rovera G, Santoli D.

J Clin Invest. 1994 Sep;94(3):1076-84.

32.

An effective and safe marrow purging strategy using a lethally irradiated killer T cell clone.

Cesano A, Pierson G, Santoli D.

Prog Clin Biol Res. 1994;389:165-73. No abstract available.

PMID:
7700898
33.

Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.

Cesano A, Visonneau S, Clark SC, Santoli D.

J Immunol. 1993 Sep 15;151(6):2943-57.

PMID:
8104216
34.

Establishment of a karyotypically normal cytotoxic leukemic T-cell line from a T-ALL sample engrafted in SCID mice.

Cesano A, O'Connor R, Nowell PC, Lange B, Clark SC, Santoli D.

Blood. 1993 May 15;81(10):2714-22.

PMID:
8490180
35.

Effects of interleukin-11 on the proliferation and cell cycle status of myeloid leukemic cells.

Hu JP, Cesano A, Santoli D, Clark SC, Hoang T.

Blood. 1993 Mar 15;81(6):1586-92.

PMID:
8453105
36.
37.
38.

Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.

Perussia B, Chan SH, D'Andrea A, Tsuji K, Santoli D, Pospisil M, Young D, Wolf SF, Trinchieri G.

J Immunol. 1992 Dec 1;149(11):3495-502.

PMID:
1358972
41.

Interleukin 4 inhibits IL-2-induced proliferation of a human T-leukemia cell line without interfering with p56-LCK kinase activation.

Torigoe T, O'Connor R, Fagard R, Fischer S, Santoli D, Reed JC.

Cytokine. 1992 Sep;4(5):369-76.

PMID:
1420998
43.

Interleukin-3 regulates the activity of the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines.

Torigoe T, O'Connor R, Santoli D, Reed JC.

Blood. 1992 Aug 1;80(3):617-24.

PMID:
1638019
44.

Pediatric leukemia/lymphoma with t(8;14)(q24;q11).

Lange BJ, Raimondi SC, Heerema N, Nowell PC, Minowada J, Steinherz PE, Arenson EB, O'Connor R, Santoli D.

Leukemia. 1992 Jul;6(7):613-8. Review.

PMID:
1385638
45.

The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias.

Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, Santoli D.

Oncogene. 1992 May;7(5):827-36.

PMID:
1570153
46.

Regulation of SRC-family protein tyrosine kinases by interleukins, IL-2, and IL-3.

Torigoe T, O-Connor R, Fagard R, Fischer S, Santoli D, Reed JC.

Leukemia. 1992;6 Suppl 3:94S-97S.

PMID:
1602836
48.

Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice.

Cesano A, O'Connor R, Lange B, Finan J, Rovera G, Santoli D.

Blood. 1991 Jun 1;77(11):2463-74.

PMID:
2039829
49.

Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro.

O'Connor R, Cesano A, Lange B, Finan J, Nowell PC, Clark SC, Raimondi SC, Rovera G, Santoli D.

Blood. 1991 Apr 1;77(7):1534-45.

PMID:
1706955
50.

Growth factor-dependent differentiation along the myeloid and lymphoid lineages in an immature acute T lymphocytic leukemia.

O'Connor R, Cesano A, Kreider BL, Lange B, Clark SC, Nowell PC, Finan J, Rovera G, Santoli D.

J Immunol. 1990 Dec 1;145(11):3779-87.

PMID:
2246514

Supplemental Content

Loading ...
Support Center